QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: mol.108.049783v1 mol.108.049783v3 74/5/1308    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gonzalez-Cabrera, P. J. Articles by Rosen, H. Search for Related Content PubMed PubMed Citation Articles by Gonzalez-Cabrera, P. J. Articles by Rosen, H.

Full Pharmacological Efficacy of a Novel S1P₁ Agonist That Does Not Require S1P-Like Headgroup Interactions

Departments of Chemical Physiology & Immunology (P.J.G.-C., E.J., M.G.S., N.L., D.M., H.R.), Chemistry (M.G., E.R.), and the Scripps Research Institute Molecular Screening Center (M.-T.S., J.C., S.B., H.R.), La Jolla, California

Strong evidence exists for interactions of zwitterionic phosphate and amine groups in sphingosine-1 phosphate (S1P) to conserved Arg and Glu residues present at the extracellular face of the third transmembrane domain of S1P receptors. The contribution of Arg¹²⁰ and Glu¹²¹ for high-affinity ligand-receptor interactions is essential, because single-point R¹²⁰A or E¹²¹A S1P₁ mutants neither bind S1P nor transduce S1P function. Because S1P receptors are therapeutically interesting, identifying potent selective agonists with different binding modes and in vivo efficacy is of pharmacological importance. Here we describe a modestly water-soluble highly selective S1P₁ agonist [2-(4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl amino) ethanol (CYM-5442)] that does not require Arg¹²⁰ or Glu¹²¹ residues for activating S1P₁-dependent p42/p44 mitogen-activated protein kinase phosphorylation, which defines a new hydrophobic pocket in S1P₁. CYM-5442 is a full agonist in vitro for S1P₁ internalization, phosphorylation, and ubiquitination. It is noteworthy that CYM-5442 was a full agonist for induction and maintenance of S1P₁-dependent blood lymphopenia, decreasing B lymphocytes by 65% and T lymphocytes by 85% of vehicle. Induction of CYM-5442 lymphopenia was dose- and time-dependent, requiring serum concentrations in the 50 nM range. In vitro measures of S1P₁ activation by CYM-5442 were noncompetitively inhibited by a specific S1P₁ antagonist [(R)-3-amino-(3-hexylphenylamino)-4-oxobutylphosphonic acid (W146)], competitive for S1P, 2-amino-2-(4-octylphenethyl)propane-1,3-diol (FTY720-P), and 5-[4-phenyl-5-(trifluoromethyl)-2-thienyl]-3-[3-(trifluoromethyl)phenyl]-1,2, 4-oxadiazole (SEW2871). In addition, lymphopenia induced by CYM-5442 was reversed by W146 administration or upon pharmacokinetic agonist clearance. Pharmacokinetics in mice also indicated that CYM-5442 partitions significantly in central nervous tissue. These data show that CYM-5442 activates S1P₁-dependent pathways in vitro and to levels of full efficacy in vivo through a hydrophobic pocket separate from the orthosteric site of S1P binding that is headgroup-dependent.

Received for publication June 19, 2008.

Accepted for publication August 15, 2008.

Address correspondence to: Hugh Rosen, 10550 North Torrey Pines Rd, ICND-118, La Jolla, CA 92037. E-mail: hrosen{at}scripps.edu

This article has been cited by other articles:

				J.-J. Liao, M.-C. Huang, K. Fast, K. Gundling, M. Yadav, J. R. Van Brocklyn, M. R. Wabl, and E. J. Goetzl Immunosuppressive human anti-lymphocyte autoantibodies specific for the type 1 sphingosine 1-phosphate receptor FASEB J, June 1, 2009; 23(6): 1786 - 1796. [Abstract] [Full Text] [PDF]